@entity5 of the ovary: prognostic factor and response of adjuvant XXXX -based chemotherapy.

@entity1 @entity902 @entity5
OBJECTIVES: The purpose of the present study was to analyse retrospectively the data of a series of @entity1 presenting to our unit with @entity5 ( @entity5 ) of the ovary to identify the prognostic factors and relate them to survival. The role of @entity902 -based chemotherapy in the adjuvant treatment of this @entity5 was also evaluated. METHODS: All @entity1 diagnosed with @entity5 of the ovary from 1987 to 2000 were identified from the gynaecological @entity5 registry of King George V Hospital, Australia. The effect of clinical and histopathological variables on survival was analysed. The response of @entity902 -based adjuvant chemotherapy after surgery was also evaluated. RESULTS: Twenty @entity1 with @entity5 of the ovary were identified. Of the six @entity1 with measurable disease, two (33%) had complete response after adjuvant @entity902 -based chemotherapy. The median survival of all @entity1 was 8 months, while that of the @entity1 receiving adjuvant @entity902 -based chemotherapy was 23 months. @entity1 who were older (> 65 years) had a significantly worse survival rate than those who were younger (P = 0.02). The @entity1 with optimal debulking had a better median survival than those with suboptimal debulking, but this difference was not statistically significant (P = 0.21). Sarcomatous component (homologous vs heterologous) was not found to be a significant prognostic factor for predicting survival. CONCLUSIONS: @entity5 of the ovary is a rare and aggressive gynaecological @entity5 . The current study indicates that @entity1 age was a significant prognostic factor for survival and surgical cytoreduction combined with @entity902 -based chemotherapy is the most effective management regimen identified to date to treat @entity5 of the ovary.
